-
Mashup Score: 2AI in Cancer Care - 1 month(s) ago
The prelude to a new era
Source: albertomussetti.substack.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5Coping in patients with hematologic malignancies undergoing hematopoietic cell transplantation - 1 month(s) ago
Coping strategies before HCT are associated with pre-HCT quality-of-life and psychological distress.Supportive care interventions during HCT to promote app
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 13Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production - 1 month(s) ago
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the formation of autoantibodies that lead to immune complex-induced inflammation in an array of different organs including the kidneys, heart, lungs and skin. The pathogenesis of SLE is complex and relies on genetic, endogenous, environmental and immunoregulatory factors1. The central role of B cells in SLE is supported by the presence of B cells in diseased tissues, clonal expansion and plasmablast generation. Monoclonal antibodies that disrupt B cell activation or deplete B cells have been used to treat autoimmune diseases like SLE.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
Nature Medicine – A large-scale study examined the heterogeneous effects of artificial intelligence (AI) assistance on 140 radiologists across 15 chest X-ray diagnostic tasks and found that…
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Generative artificial intelligence and scientific publishing: urgent questions, difficult answers - 1 month(s) ago
Azeem Azhar describes, in Exponential: Order and Chaos in an Age of Accelerating Technology, how human society finds it hard to imagine or process exponential growth and change and is repeatedly caught out by this phenomenon.1 Whether it is the exponential spread of a virus or the exponential spread of a new technology, such as the smartphone, people consistently underestimate its impact. Azhar argues that an exponential gap has developed between technological progress and the pace at which institutions are evolving to deal with that progress.
Source: www.thelancet.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies—idecabtagene vicleucel (ide-cel; Bristol Myers Squibb), and ciltacabtagene autoleucel (cilta-cel; Janssen Biotech)—have been approved by the US Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody [1–3]. The 2 products have shown unprecedented activity in RRMM, but relapse remains common in the late-line setting, where many patients have bulky, rapidly growing high-risk disease that may decrease both efficacy and safety.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 46
Bone Marrow Transplantation – Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 46
Bone Marrow Transplantation – Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 13Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice - 2 month(s) ago
Key Points. Pretransplant single dose CD45-ADC conditioning effectively promoted alloengraftment with low toxicity in 3 Fanconi anemia mouse models.Donor T cell
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 26Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study. - 2 month(s) ago
The outcome of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the three main classes of myeloma therapy [immunomodulatory drugs (Imids), proteasome inhibitors (PI), and anti-CD38 antibodies (anti-CD38)] remains poor. However, in the KarMMa trial1, the use of idecabtagene vicleucel (ide-cel), an autologous B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) showed improved response with prolonged overall survival (OS) and progression-free survival (PFS) among heavily treated patients.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
Welcome to the first post of ByteMed - #AI in #Medicine. A selection of weekly articles related to artificial intelligence applied to Medicine. Stay updated, ride the AI wave!😉 AI in Cancer Care https://t.co/txxBmBE5kb